Comparison of Single Antiplatelet Therapy and Dual Antiplatelet Therapy after Endovascular Therapy in Patients with Lower Extremity Artery Disease

Figures

• 

  Fig. 1 Study flow diagram. DAPT: dual antiplatelet therapy; EVT: endovascular therapy; LEAD: lower extremity artery disease; OAC: oral anticoagulant; SAPT: single antiplatelet therapy

• 

  Fig. 2 Bleeding events. (A) The Kaplan-Meier estimate showed rates of cumulative bleeding events of 14.2% in the SAPT group and 11.3% in the DAPT group at 24 months (p = 0.775). (B) Landmark analysis presented that rates of cumulative bleeding events in the SAPT group and the DAPT group were 2.5% and 6.1% at 30 days (p = 0.106) and 11.7% and 6.7% at 24 months after 30 days, respectively (p = 0.162). DAPT: dual antiplatelet therapy; SAPT: single antiplatelet therapy

• 

  Fig. 3 Ischemic events. The rates of cumulative ischemic events estimated using the Kaplan-Meier method were 32.7% in the SAPT group and 30.6% in the DAPT group at 24 months. There was no significant difference between the two groups (p = 0.625). DAPT: dual antiplatelet therapy; SAPT: single antiplatelet therapy

• 

  Fig. 4 Bleeding events in each subgroup. Bleeding events at 24 months between the SAPT and DAPT groups occurred at (A) 10.6% and 11.4% and 17.1% and 11.2% in the non-DM and DM groups, respectively (p = 0.685 and p = 0.472); (B) 11.2% and 7.2% and 22.0% and 27.0% in the non-HD and HD groups (p = 0.442 and p = 0.57); (C) 8.9% and 9.2% and 25.7% and 15.2% in the non-CLTI and CLTI groups (p = 0.735 and p = 0.453); and (D) 11.9% and 11.7%, 14.6% and 9.8%, and 24.9% and 17.9% in the AI, FP, and BK segments, respectively (p = 0.969, p = 0.698, and p = 0.721). There were no significant differences between the subgroups. AI: aortoiliac; BK: below-knee; CLTI: chronic limb-threatening ischemia; DAPT: dual antiplatelet therapy; DM: diabetes mellitus; FP: femoropopliteal; HD: hemodialysis; SAPT: single antiplatelet therapy

• 

  Fig. 5 Ischemic events in each subgroup. Ischemic events at 24 months between the SAPT and DAPT groups occurred at (A) 26.7% and 24.7% and 37.2% and 34.8% in the non-DM and DM groups, respectively (p = 0.941 and p = 0.535); (B) 29.4% and 25.3% and 40.7% and 49.1% in the non-HD and HD groups (p = 0.63 and p = 0.97); (C) 28.7% and 28.4% and 40.7% and 36.8% in the non-CLTI and CLTI groups (p = 0.984 and p = 0.394); and (D) 20.0% and 25.6%, 39.2% and 32.4%, and 33.6% and 39.0% in the AI, FP, and BK segments, respectively (p = 0.439, p = 0.268, and p = 0.964). There were no significant differences between the subgroups. AI: aortoiliac; BK: below-knee; CLTI: chronic limb-threatening ischemia; DAPT: dual antiplatelet therapy; DM: diabetes mellitus; FP: femoropopliteal; HD: hemodialysis; SAPT: single antiplatelet therapy